Brd4 was identified as a promising therapeutic target for AML (60, 61, 117) (Table 1), and targeting Brd4 using small hairpin RNAs or small molecule inhibitors resulted in a strong anti-leukemia effect, terminal myeloid differentiation and elimination of LSCs (60). This evidence concerns the gene BRD4 and acute myeloid leukemia.